Pulmonary Hypertension KOL Interview - France

This interview with a France-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1-5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, Ventavis, Veletri, Flolan, Revatio, Letairis, INOpulse, and sotatercept.